---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000037"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:55:05.421962+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# FDA approves Krystal Biotech's VYJUVEK gene therapy for DEB; first redosable gene therapy

## Summary
- FDA approval of VYJUVEK (beremagene geperpavec-svdt) for dystrophic epidermolysis bullosa (DEB) patients aged 6 months+.
- Phase 3 GEM-3 trial met primary endpoint of complete wound healing at six months and key secondary endpoint at three months.
- First-ever redosable gene therapy approved and first FDA-approved medicine for DEB (both recessive and dominant).
- Rare Pediatric Disease Priority Review Voucher granted by FDA.
- U.S. commercial launch expected Q3 2023; EU filing planned H2 2023, Japan launch targeted 2025.

## SEC filing metadata
- accession: 0001711279-23-000037
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000037/0001711279-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000037/krys-20230519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000037
- JSON: https://secwatch.observer/filing/0001711279-23-000037.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.